USTAR BIOTECHNOLOGIES (HANGZHOU) LTD. was established in 2005, dedicated to the research, development, manufacturing and sales of innovative point-of-care molecular diagnostic technology and products. We have established a technical platform with completely independent IP rights, and applied for over 90 international and domestic invention patents, including 45 authorized patents. Ustar keeps participating in national projects for the prevention and control of infectious diseases, and has won dozens of national grants and awards. Our nucleic acid amplification and detection analyzer was certified by National Medical Products Administration (NMPA) through the emergency approval channel in 2019; the COVID-19 nucleic acid test kit obtained NMPA registration certificate in early 2020 as the first domestic approved listed COVID-19 molecular POCT product. Ustar’s POCT kits integrate nucleic acid extraction, purification, amplification and test in an enclosed cartridge to achieve a fast, accurate, simple and safe test with LOD≤200 copies/mL.

Ustar's products have served nearly 3,000 medical institutions and exported to over 70 countries, actively contributing to the global prevention and control of major infectious diseases such as COVID-19 and tuberculosis. Our vision is to make molecular tests available to anyone, anywhere, as stated in our slogan, Molecular Testing Anywhere !